1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Rijnstate Hospital
- Enrollment
- 234
- Locations
- 1
- Primary Endpoint
- Pulmonary function abnormalities
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The aim of the present study is:
- To investigate pulmonary function abnormalities (restriction, obstruction, diffusion impairment, mixed pulmonary defects) in patients with chronic heart failure (CHF) and to determine which of these pulmonary abnormalities prevail and to what extent.
- To determine the prevalence, underdiagnosis, and overdiagnosis of chronic obstructive pulmonary disease (COPD) as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
- To investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.
Detailed Description
1. The impact of chronic heart failure (CHF) on pulmonary function is incompletely understood and remains controversial. It is difficult to separate the contribution of stable CHF from underlying pulmonary disease and other confounding influences, such as changes due to normal ageing, obesity, environmental exposure (mainly smoking), stability of disease, a history of coronary artery bypass grafting, and other conditions that can lead to pulmonary function abnormalities. Studies have shown that isolated or combined pulmonary function impairment, such as diffusion impairment, restriction, and to a much lesser extent airway obstruction are common in patients with CHF and can contribute to the perception of dyspnoea and exercise intolerance. Pulmonary dysfunction increases with the severity of heart failure and provides important prognostic information. Most investigators compared pulmonary function in CHF patients with normal predicted values or control subjects. However, there is only a small body of literature addressing the prevalence of different pulmonary function abnormalities in patients with CHF. In addition, these studies have included (potential) heart transplant recipients, who represent one extreme of the heart failure spectrum. The aim of the present study was to investigate the prevalence of pulmonary function abnormalities in patients with CHF and to determine which of these pulmonary abnormalities prevail and to what extent. 2. Chronic obstructive pulmonary disease (COPD) frequently coexists with CHF, leading to impaired prognosis as well as diagnostic and therapeutic challenges. However, lung functional data on COPD prevalence in CHF are scarce and COPD remains widely undiagnosed or misdiagnosed. The reported prevalence rates of COPD range from 9 to 41% in European cohorts and from 11 to 52% in North American patients with heart failure. The purpose of this study was to determine the prevalence, underdiagnosis, and overdiagnosis of COPD as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF. 3. There is abundant evidence of increased systemic inflammation in both CHF and COPD and it is remarkable to observe the similarities of inflammation in both conditions. These inflammatory responses may provide a mechanistic bridge between COPD and cardiac co-morbidity. However, there is no information regarding systemic inflammation when CHF and COPD coexist. It is unknown whether the combination of these two diseases leads to increased systemic inflammation in comparison to CHF alone. The aim of this study was to investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chronic heart failure patients with left ventricular systolic dysfunction (left ventricular ejection fraction \< 40%)
- •Outpatients
- •New York Heart Association (NYHA) class I-IV
- •18 years and older
- •Informed consent
Exclusion Criteria
- •Patients who do not meet the inclusion criteria
- •Patients who are not able to cooperate or undergo pulmonary function tests
- •Other diseases that can lead to obstructive lung function: asthma, cystic fibrosis
- •Malignancy with bad prognosis (survival \< 6 months)
- •Hospitalisation to the pulmonary department in the past 6 weeks, in this case patients will have the pulmonary function tests ≥ 6 weeks after discharge
- •Patients who are already participating in another study within the cardiology department
- •Additional exclusion criteria for the first primary objective:
- •Disorders/diseases that can lead to pulmonary function impairment:
- •Pulmonary: lung surgery (lobectomy/pneumectomy), parenchymal neoplasms, interstitial lung disease, sarcoidosis, pneumoconioses, lung abscess, lobar pneumonia, post- infectious scarring, atelectasis, radiation fibrosis
- •Pleural: diffuse pleural thickening, mesothelioma, pleural effusion not due to heart failure, pneumothorax
Outcomes
Primary Outcomes
Pulmonary function abnormalities
Time Frame: 1 day
Restriction, obstruction, diffusion impairment, mixed pulmonary defects
Systemic inflammation
Time Frame: 1 day
Leukocytes, platelets, high sensitivity CRP.
COPD prevalence, underdiagnosis, and overdiagnosis
Time Frame: 3 months
Patients with newly diagnosed COPD repeated spirometry after 3 months of standard treatment for COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
Secondary Outcomes
- Dyspnoea(3 months)
- Quality of life(3 months)
- Independent predictors of COPD(3 months)